Lupin Gains FDA Approval for Generic Pitolisant Tablets
Event summary
- Lupin received final FDA approval for its ANDA for Pitolisant Tablets in 4.45 mg and 17.8 mg strengths.
- The tablets are bioequivalent to Bioprojet Europe's Wakix® for approved indications.
- Lupin is a global pharmaceutical company with operations in over 100 markets.
- The company operates 15 manufacturing sites and 6 research centers worldwide.
The big picture
Lupin's FDA approval for Pitolisant Tablets marks its entry into the narcolepsy treatment market, competing directly with Bioprojet Europe's Wakix®. This approval strengthens Lupin's portfolio in the central nervous system therapy area, a key growth segment for the company. The move aligns with broader industry trends of generic drug manufacturers targeting complex therapeutics to expand market reach and revenue streams.
What we're watching
- Market Share Impact
- How quickly Lupin can capture market share from Bioprojet Europe's Wakix®.
- Pricing Strategy
- Whether Lupin can maintain competitive pricing while ensuring profitability.
- Regulatory Compliance
- The pace at which Lupin can navigate additional regulatory hurdles for similar products.
Related topics